Skip to content

A multicenter, prospective, real-world study on the efficacy and safety of taurine ursodeoxycholic acid capsule in the treatment of dyspepsia complications after cholecystectomy in patients with gallstones

A multicenter, prospective, real-world study on the efficacy and safety of taurine ursodeoxycholic acid capsule in the treatment of dyspepsia complications after cholecystectomy in patients with gallstones

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069942
Enrollment
Unknown
Registered
2023-03-29
Start date
2023-03-31
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia after cholecystectomy

Interventions

Test group:Take taurine ursodeoxycholic acid capsule

Sponsors

Hunan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Subjects must meet all the following inclusion criteria to be enrolled in this study: 1. Age 18-80 (including boundary value), gender unlimited; 2. Cholecystolithiasis was diagnosed by imaging examination and cholecystectomy was performed; 3. Symptoms of dyspepsia (such as anorexia, early satiety, belching, nausea and vomiting, abdominal distension, abdominal pain/abdominal discomfort, diarrhea, reflux, etc.) occur when returning to the hospital after surgery; 4. Researchers believe that taurine ursodeoxycholic acid capsules can be taken when dyspepsia occurs; 5. The subjects expressed informed consent, volunteered to be tested and signed the informed consent form, and agreed to participate in all visits and inspections according to the requirements of the test protocol.

Exclusion criteria

Exclusion criteria: Subjects will be excluded if they meet any of the following conditions: 1. Postoperative dyspepsia caused by other organic diseases; 2. It is complicated with serious disease or mental disease that affects its survival, or known or confirmed active ulcer or duodenal ulcer, or other conditions that are judged by the researcher to be unsuitable for participation in this clinical trial; 3. Those who are allergic to any ingredient contained in taurine ursodeoxycholic acid capsules, or those with allergic constitution.

Design outcomes

Primary

MeasureTime frame
Change of dyspepsia symptom score from baseline;Change in quality of life score from baseline;Changes of bile reflux score and gastric mucosa score from baseline;

Countries

China

Contacts

Public ContactWei Cheng

Hunan Provincial People's Hospital

13974866177@163.com+86 139 7486 6177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026